<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H6F3C66C14D144452897CA65CFB315C1C" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 7474 IH: Pharmaceutical Research Transparency Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-04-07</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7474</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220407">April 7, 2022</action-date><action-desc><sponsor name-id="M000087">Mrs. Carolyn B. Maloney of New York</sponsor> (for herself, <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>, <cosponsor name-id="W000800">Mr. Welch</cosponsor>, <cosponsor name-id="P000618">Ms. Porter</cosponsor>, <cosponsor name-id="D000623">Mr. DeSaulnier</cosponsor>, and <cosponsor name-id="R000606">Mr. Raskin</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HBA00">Financial Services</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Public Health Service Act to increase the transparency of pharmaceutical research costs, and for other purposes.</official-title></form><legis-body id="H85C1D8F39A314D23B07838D385BBE99A" style="OLC"><section section-type="section-one" id="HD2A219DF2A7B43EA8D523CA7FCCE0A4D"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Pharmaceutical Research Transparency Act of 2022</short-title></quote>.</text></section><section id="H99F7DCA5BB61460FB0F68BB3EA19CF9B"><enum>2.</enum><header>Expansion of registry and results data bank to include costs of drug clinical trials</header><subsection id="HBAFAAA41FC7A440B846F517F3C9B01B0"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 402(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)</external-xref>) is amended—</text><paragraph id="H6BE910585D4B419E93FF086E1B5DA451"><enum>(1)</enum><text display-inline="yes-display-inline">by redesignating paragraph (7) as paragraph (8); and</text></paragraph><paragraph id="HFCBD14E271604799980BA3A1E8154446"><enum>(2)</enum><text display-inline="yes-display-inline">by inserting after paragraph (6) the following new paragraph:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HDAB6C91855AA4CCC8B426200667F691E"><paragraph id="H3DA859FE38774977BAB2B1AF4659FD9A"><enum>(7)</enum><header>Creation of clinical trial cost data repository</header><subparagraph id="HE5721B328D084437BF8CF9619200172C"><enum>(A)</enum><header>Generally</header><text display-inline="yes-display-inline">The Secretary, acting through the Director of NIH, shall create a publicly available Federal website to serve as a repository of cost data for all applicable drug clinical trials (in this paragraph referred to as the <quote>cost data repository</quote>). Such repository shall be searchable by the following criteria:</text><clause id="H0BCC3FB3B82841629044468FA2A6128C"><enum>(i)</enum><text display-inline="yes-display-inline">The responsible party or sponsor of the applicable drug clinical trial, or any entity funding the applicable drug clinical trial.</text></clause><clause id="H4E8928A8B72B410284B080DD2A9A807C"><enum>(ii)</enum><text>The name of the intervention, including any drug being studied in the applicable drug clinical trial.</text></clause><clause id="H2BFD46953F7C45BCB8FCF6BBFEAC0009"><enum>(iii)</enum><text>The study phase of the applicable drug clinical trial.</text></clause><clause id="HC0343D54CA5949F1B3AF3CB8B4BD6D93"><enum>(iv)</enum><text>The start date and completion date of the applicable drug clinical trial.</text></clause><clause id="H1FA625BB6B904A8A977E3873BBA967D6"><enum>(v)</enum><text>Such other criteria as the Secretary deems appropriate.</text></clause></subparagraph><subparagraph id="H99A6BA78FB9148C88D74AA313A4438EE"><enum>(B)</enum><header>Cost data defined</header><text display-inline="yes-display-inline">For purposes of this paragraph, the term <term>cost data</term> includes the following information: </text><clause id="H6DF8B735AF5F42F497B3688A6B1E2BAB"><enum>(i)</enum><text>The total cost of the applicable drug clinical trial.</text></clause><clause id="H788A55CBBABD42D781A7C3177E8C4B78"><enum>(ii)</enum><text>The cost of the trial per patient.</text></clause><clause id="HC32BF4BDC6594A2EAE850A6BA592E6C5"><enum>(iii)</enum><text>Expenditures for each of the following categories:</text><subclause id="H5C0CD1015B614D4191E3E12BA8226D04"><enum>(I)</enum><text>Personnel.</text></subclause><subclause id="H5420D6AEB8E54F84A046611BCEBDEEFD"><enum>(II)</enum><text>Any intervention or treatment that is administered in one or more arms of the applicable drug clinical trial.</text></subclause><subclause id="HC515F7EAE2144A3EB55AC8761E4C19CA"><enum>(III)</enum><text>Materials and supplies.</text></subclause><subclause id="H44562AF0053442E7A5BAFE82986ECCEE"><enum>(IV)</enum><text>Health care services provided to subjects.</text></subclause><subclause id="HDD52B73337134971A43A12150734F78C"><enum>(V)</enum><text>Site management.</text></subclause><subclause id="HF9FB2F4450CF43219731F71B029D2E31"><enum>(VI)</enum><text>Laboratory.</text></subclause><subclause id="H553FEE71ED4142008452282962504560"><enum>(VII)</enum><text>Equipment.</text></subclause><subclause id="H9860CFC1FEBD4525BA4BFB92BA4654DE"><enum>(VIII)</enum><text>The allocable portion of any facilities costs, administrative costs, or other costs that are not solely attributable to the applicable drug clinical trial.</text></subclause><subclause id="HF6E96638EBAB477387046C2B882FB17F"><enum>(IX)</enum><text>Such other categories as the Secretary may identify by regulation.</text></subclause></clause></subparagraph><subparagraph id="H158BA60CF9094321B3F65894F14F0443"><enum>(C)</enum><header>Posting of clinical trial cost data</header><clause id="H79A43314769540F389C0153CE92A8919"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">Except as provided in clause (iii), each responsible party of an applicable drug clinical trial shall post cost data for that trial to the cost data repository no later than 1 year after the completion date of the trial.</text></clause><clause id="H34D9C67803164EE3B519747F79F2C5CA"><enum>(ii)</enum><header>Format and methodology of posting</header><text>A cost data posting under clause (i) shall—</text><subclause id="H809C539578ED4F9DAE20547A2A038261"><enum>(I)</enum><text>include individual data points for the information required under subparagraphs (B)(i) and (B)(ii), separated by year;</text></subclause><subclause id="H9832D1CA69414B62B2B7FB7216E67AEC"><enum>(II)</enum><text>include individual data points for each category listed under subparagraph (B)(iii), separated by year;</text></subclause><subclause id="H4B2ED194082142528DA9E83825148C99"><enum>(III)</enum><text>limit the cost of the intervention or treatment under subparagraph (B)(iii)(II) to manufacturing costs unless the responsible party of the trial was required to purchase the intervention or treatment from an unaffiliated third party; </text></subclause><subclause id="H772E1016DFCE4466A0FD77B77869F6C5"><enum>(IV)</enum><text>include detailed documentation and methodology for the calculation of costs identified under subparagraph (B)(iii)(VIII); and</text></subclause><subclause id="HD0BF54A6D3BE468C908C7049DCD8A6F2"><enum>(V)</enum><text display-inline="yes-display-inline">include a signed certification that the posted data is complete and accurate.</text></subclause></clause><clause id="H3AA761D12B694042B0B73293014ACA1F"><enum>(iii)</enum><header>Delayed posting of cost data and extensions</header><subclause id="H6FEDCB310126412BBF581CEF502FAC73"><enum>(I)</enum><header>Seeking initial approval of drug, or approval of a new use</header><text>If the responsible party for an applicable drug clinical trial submits a certification that paragraph (3)(E)(iv) or paragraph (3)(E)(v) applies to such trial, the responsible party shall post cost data under clause (i) at the time that clinical trial information is required to be submitted under the applicable paragraph.</text></subclause><subclause id="HB71B4658005749A692E7AEB747B8050E"><enum>(II)</enum><header>Extension for good cause</header><text>The Director of NIH may provide an extension of the deadline for posting of cost data under clause (i) if the responsible party for the trial submits to the Director a written request that demonstrates good cause for the extension and provides an estimate of the date on which the information will be posted. The Director of NIH may grant more than one such extension for a clinical trial, but under no circumstances shall an extension under this subclause extend beyond the date that is 18 months after the completion date of the trial.</text></subclause><subclause id="H0A7F261C61B14572A56F84CC67F59EA2"><enum>(III)</enum><header>Extension to establish necessary infrastructure</header><text>If necessary to establish the necessary infrastructure to accept, organize, and post cost data submitted under clause (i), the Director of NIH may extend the deadline for the posting of cost data under clause (i) to not later than 2 years after the date of enactment of the <short-title>Pharmaceutical Research Transparency Act of 2022</short-title>.</text></subclause><subclause id="H34A75B8ACD914D80ACFFDD92EB26B525"><enum>(IV)</enum><header>Rule of construction</header><text>This clause shall not be construed to have any effect on reporting obligations of the responsible party under provisions other than this paragraph.</text></subclause></clause></subparagraph><subparagraph id="HA712CED71BC242A8959D897915B72D04"><enum>(D)</enum><header>Linking to cost data repository</header><clause id="H073B49DF33CD4D3EBCE468CCC291C37B"><enum>(i)</enum><header>Creation of field</header><text display-inline="yes-display-inline">The Director of NIH shall create a field within the registry and results data bank to include an electronic link to the relevant cost data posting under subparagraph (C)(i).</text></clause><clause id="HE5D22E38658949159510A55F0C4F29E8"><enum>(ii)</enum><header>Posting</header><text display-inline="yes-display-inline">The responsible party for an applicable drug clinical trial shall post in the field created under clause (i) a link to the relevant cost data posting no later than 5 days after initial posting of the cost data under subparagraph (C)(i). </text></clause></subparagraph><subparagraph id="H5FC63B79C750462AB10F67E1B4C42412"><enum>(E)</enum><header>Rulemaking</header><clause id="HC06A72533D65484CA3981BF8EC1E8D56"><enum>(i)</enum><header>In general</header><text>The Secretary shall promulgate regulations to carry out this paragraph that include—</text><subclause id="HDAFB8931DE624563BE2952966B6D2DCC"><enum>(I)</enum><text>definitions for each category of information identified in subparagraph (B);</text></subclause><subclause id="HF91A05D7477E4041AF4A95B78BBA1AAF"><enum>(II)</enum><text>standards for allocating fixed expenditures across multiple years of an applicable drug clinical trial;</text></subclause><subclause id="HF780D90B7F8547A8B8ABD4288F307111"><enum>(III)</enum><text>a standard format for the submission and posting of cost data under this paragraph;</text></subclause><subclause id="HED49125DF1B44138B2D1684A1A787122"><enum>(IV)</enum><text>procedures, standards, and requirements for the reporting documentation and methodology required under subparagraph (C)(ii)(IV); and</text></subclause><subclause id="HC3E05442F43A449CB11DA0A968851C5A"><enum>(V)</enum><text>any other procedures, standards, or requirements necessary to ensure public transparency of cost data as required by this paragraph.</text></subclause></clause><clause id="H54A15324A17C4BB1A098ADDBAC150F6B"><enum>(ii)</enum><header>Initial regulations</header><text display-inline="yes-display-inline">The Secretary shall—</text><subclause id="HCFF9A2D43BC3423F9BDC12B52C2ADD40"><enum>(I)</enum><text>not later than one year after the date of enactment of the <short-title>Pharmaceutical Research Transparency Act of 2022</short-title>, propose initial regulations under clause (i); and</text></subclause><subclause id="H055005BF67424EFD95FA19D9D23B70C1"><enum>(II)</enum><text>not later than 2 years after such date of enactment, finalize such regulations.</text></subclause></clause></subparagraph><subparagraph id="H175FB488B0B843698654F97EDED482CD"><enum>(F)</enum><header>Applicability</header><text>The requirements of this paragraph apply only to applicable drug clinical trials with a start date on or after the date of enactment of the <short-title>Pharmaceutical Research Transparency Act of 2022</short-title>.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H69690AAA28E44CC091E50833CE05A4CB"><enum>(b)</enum><header>Conforming changes</header><text display-inline="yes-display-inline">Section 402(j) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/282">42 U.S.C. 282(j)</external-xref>), as amended by subsection (a), is further amended—</text><paragraph id="H5955BA6A846F489C81EAE05D79A62DD7"><enum>(1)</enum><text>in paragraph (1)(A)(iv), by striking <quote>paragraph (2) or under paragraph (3)</quote> and inserting <quote>paragraph (2), (3), or (7)</quote>;</text></paragraph><paragraph id="H8105D9D1B23F42E39584FE91602F1F9A"><enum>(2)</enum><text display-inline="yes-display-inline">in paragraph (4)—</text><subparagraph id="H539FBDA0C1774805A7543036D74EAB9D"><enum>(A)</enum><text>in subparagraph (A), by striking <quote>paragraph (2) or paragraph (3)</quote> and inserting <quote>paragraph (2), (3), or (7)</quote>; and</text></subparagraph><subparagraph id="H28917ECA65FC461183D382C3E4424AF2"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (B)(i), by striking <quote>paragraphs (2) and (3)</quote> each place it appears and inserting <quote>paragraphs (2), (3), and (7)</quote>; and</text></subparagraph></paragraph><paragraph id="H3C7A02154A7A453AB538B1FCBD5F4267"><enum>(3)</enum><text display-inline="yes-display-inline">in paragraph (5)—</text><subparagraph id="HCE5F974A7DE346408F007BD802105934"><enum>(A)</enum><text>in subparagraph (A), by striking <quote>paragraphs (2) and (3)</quote> each place it appears and inserting <quote>paragraphs (2), (3), and (7)</quote>; and</text></subparagraph><subparagraph id="H85A5AA4F739B4A87AFD5DC089CC41A8F"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (E)(i), by striking <quote>paragraphs (2) or (3)</quote> and inserting <quote>paragraph (2), (3), or (7)</quote>.</text></subparagraph></paragraph></subsection></section><section commented="no" id="H33BAFD84568F4DA4AADD7244F8B2D2F5"><enum>3.</enum><header>Disclosure of research and development expenditures by drug manufacturers</header><text display-inline="no-display-inline">Section 13 of the Securities Exchange Act of 1934 (<external-xref legal-doc="usc" parsable-cite="usc/15/78m">15 U.S.C. 78m</external-xref>) is amended by adding at the end the following:</text><quoted-block id="H0E765F14EA724155AD7E7B2E0BDD4DB6" display-inline="no-display-inline" style="OLC"><subsection commented="no" id="H4525E280C8604497984A7D1FA4F129FD"><enum>(s)</enum><header>Disclosure of research and development expenditures by drug manufacturers</header><paragraph commented="no" id="H2452CBB0D718442BBCE4583D34A39338"><enum>(1)</enum><header>Definitions</header><text>In this subsection:</text><subparagraph commented="no" id="H3B409CF720FB4F8F891AADFFF0D582EB"><enum>(A)</enum><header>Drug</header><text>The term <term>drug</term> means any product for which one or more components have been the subject of any of the following applications filed with the Food and Drug Administration:</text><clause commented="no" id="HF0BD5553826D4269863FF7905DCC8CCA"><enum>(i)</enum><text>A new drug application (or supplemental new drug application) filed under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>).</text></clause><clause commented="no" id="HDEA2ABF4FD504848969B9C5EE53E6B6B"><enum>(ii)</enum><text display-inline="yes-display-inline">A biologic product application (or supplemental application) filed under subsection (a) or (k) of section 351 of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262</external-xref>).</text></clause></subparagraph><subparagraph commented="no" id="HAFDE6383163A42EFB17889995BB5F6E2"><enum>(B)</enum><header>Drug manufacturer issuer</header><text>The term <term>drug manufacturer issuer</term> means an issuer that—</text><clause commented="no" id="H0E61F55CF1B04A628942328D6991C86D"><enum>(i)</enum><text>is required to file an annual report with the Commission under subsection (a); and</text></clause><clause commented="no" id="H91C89887F65746E6BAEF054026227C9B"><enum>(ii)</enum><text>engages in the development, manufacture, or marketing of any drug.</text></clause></subparagraph></paragraph><paragraph commented="no" id="H92D7B6821C364E4FBE5C710EB79E1629"><enum>(2)</enum><header>Disclosure</header><subparagraph commented="no" id="H7F64A7F1EED44028B72F131ACD043B58"><enum>(A)</enum><header>In general</header><text>Subject to the other provisions of this paragraph, the Commission shall issue rules that require each drug manufacturer issuer’s annual report under subsection (a) to include information regarding the drug manufacturer issuer’s research and development expenditures with respect to—</text><clause commented="no" id="H3055C1596BFA4D95B9788F001F3D4221"><enum>(i)</enum><text>a drug; and</text></clause><clause commented="no" id="H9C4F0CBEBD94470B81937EB65CEC07B7"><enum>(ii)</enum><text>any preliminary research or development of a drug product or drug substance, as those terms are defined in section 314.3 of title 21, Code of Federal Regulations (or any successor regulation) for which the drug manufacturer issuer has not submitted an application described in clause (i) or (ii) of paragraph (1)(A).</text></clause></subparagraph><subparagraph id="H97926F585F434D3A9F429B655ED79482"><enum>(B)</enum><header>Initial rules</header><text display-inline="yes-display-inline">The Commission shall—</text><clause id="H796DF4D4067A49B19C39569FA6754A5C"><enum>(i)</enum><text>not later than 1 year after the date of enactment of the <short-title>Pharmaceutical Research Transparency Act of 2022</short-title>, propose initial rules under subparagraph (A); and</text></clause><clause id="HD9B4F04651A043D3AB2A1872F85ABCDC"><enum>(ii)</enum><text>not later than 2 years after the date of enactment described in clause (i), finalize the rules required under subparagraph (A).</text></clause></subparagraph><subparagraph commented="no" id="H0F9D52E11F3C4244A95F253BFE8126AD"><enum>(C)</enum><header>Required information</header><text>The information required under subparagraph (A) shall include total expenditures, which shall be disaggregated to each stage of drug research and development, including—</text><clause commented="no" id="HB510F6CD956E439785BF0DD7A90281B1"><enum>(i)</enum><text>basic research;</text></clause><clause commented="no" id="H7922598871954BC39F8CA16E837264CB"><enum>(ii)</enum><text>pre-clinical research; </text></clause><clause commented="no" id="HC1EBF22B8EFB4DBBBB414D1B1B1B135A"><enum>(iii)</enum><text>phase I of a clinical investigation of a new drug, as described in section 312.21(a) of title 21, Code of Federal Regulations, or any successor regulation;</text></clause><clause commented="no" id="HF671EBEDD5AF418DB6F1E2D2D37834AE"><enum>(iv)</enum><text display-inline="yes-display-inline">phase II of a clinical investigation of a new drug, as described in section 312.21(b) of title 21, Code of Federal Regulations, or any successor regulation;</text></clause><clause commented="no" id="H3B0DFDE528114D4CB2D9B68C07FCF616"><enum>(v)</enum><text display-inline="yes-display-inline">phase III of a clinical investigation of a new drug, as described in section 312.21(c) of title 21, Code of Federal Regulations, or any successor regulation; and</text></clause><clause commented="no" id="HA5E0CA59E3FF499E828C3416D2C684B4"><enum>(vi)</enum><text>post-market studies or clinical trials required under section 505(o) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(o)</external-xref>).</text></clause></subparagraph><subparagraph commented="no" id="H7CE0F2E0770A4778997ED385ECA801F0"><enum>(D)</enum><header>Limitations calculation</header><text>The calculation of expenditure information disclosed under subparagraph (A) shall not include the following information, although such information may be disclosed separately:</text><clause commented="no" id="HFFD7156A6D4543D2910628D901D6B764"><enum>(i)</enum><text>Costs incurred in connection with licensing agreements or acquiring intellectual property.</text></clause><clause commented="no" id="HF20726B27C44490381FB6F36D0DD081E"><enum>(ii)</enum><text>The cost of mergers or acquisitions.</text></clause><clause commented="no" id="HFFAA79DDBD8440BA9E8D06191B40021B"><enum>(iii)</enum><text>Any intangible costs, including estimates, adjustments, and assumptions related to the risk of failure, or the risk associated with seeking regulatory approval by the Food and Drug Administration or another agency.</text></clause><clause commented="no" id="H678AF00E01B44058BB5111DE491C55B7"><enum>(iv)</enum><text>The estimated cost of capital.</text></clause></subparagraph></paragraph><paragraph commented="no" id="HD331633306904693B7E4E20D5CD93F21"><enum>(3)</enum><header>Consultation in rulemaking</header><text>In issuing rules under this subsection, the Commission—</text><subparagraph commented="no" id="H86462270020747E0BEE264622950DE81"><enum>(A)</enum><text>shall consult with the Commissioner of Food and Drugs and the Director of the National Institutes of Health; and</text></subparagraph><subparagraph id="H04CFF856C4AB42209548B99329D566C6" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text>may consult with the head of any other Federal agency or entity that the Commission determines is relevant.</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="H80B6240E2CA44C8CA4000A1D26B5AABF"><enum>4.</enum><header>Severability</header><text display-inline="no-display-inline">If any provision of this Act, an amendment made by this Act, or the application of any such provision or amendment to any person or circumstance is held to be unconstitutional, the remainder of the provisions of this Act, the amendments made by this Act, and the application of such provisions and amendments to any person or circumstance shall not be affected thereby.</text></section></legis-body></bill> 

